Absci Stock Soars 13.65% on FDA's AI Regulatory Shift

On April 11, 2025, Absci's stock surged by 13.65% in pre-market trading, reflecting a significant boost in investor confidence.

The U.S. Food and Drug Administration (FDA) has announced a groundbreaking shift in its regulatory approach, phasing out animal testing requirements in favor of AI-based computational models and human-relevant methods. This policy change is expected to accelerate drug development, reduce R&D costs, and lower drug prices, all of which are positive developments for companies like Absci that are at the forefront of health care technology.

The FDA's decision to replace animal tests with advanced computer simulations and human-based lab models is a major step forward in the industry. This move is anticipated to improve the overall drug development process, making it more efficient and cost-effective. Absci, with its focus on AI and computational models, is well-positioned to benefit from these regulatory changes, as they align with the company's innovative approach to drug discovery and development.